Switch theme
Sign up to access all valuation multiples
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
2017
368
LTM Revenue $251M
LTM EBITDA -$237M
$3.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SpringWorks Therapeutics has a last 12-month revenue (LTM) of $251M and a last 12-month EBITDA of -$237M.
In the most recent fiscal year, SpringWorks Therapeutics achieved revenue of $192M and an EBITDA of -$275M.
SpringWorks Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SpringWorks Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $251M | XXX | $192M | XXX | XXX | XXX |
| Gross Profit | $234M | XXX | $179M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | -$237M | XXX | -$275M | XXX | XXX | XXX |
| EBITDA Margin | -95% | XXX | -143% | XXX | XXX | XXX |
| EBIT | -$257M | XXX | -$278M | XXX | XXX | XXX |
| EBIT Margin | -103% | XXX | -145% | XXX | XXX | XXX |
| Net Profit | -$240M | XXX | -$258M | XXX | XXX | XXX |
| Net Margin | -96% | XXX | -135% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, SpringWorks Therapeutics's stock price is $47.
SpringWorks Therapeutics has current market cap of $3.5B, and EV of $3.2B.
See SpringWorks Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.2B | $3.5B | XXX | XXX | XXX | XXX | $-3.18 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, SpringWorks Therapeutics has market cap of $3.5B and EV of $3.2B.
SpringWorks Therapeutics's trades at 16.9x EV/Revenue multiple, and -11.8x EV/EBITDA.
Equity research analysts estimate SpringWorks Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SpringWorks Therapeutics has a P/E ratio of -14.7x.
See valuation multiples for SpringWorks Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.5B | XXX | $3.5B | XXX | XXX | XXX |
| EV (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV/Revenue | 12.9x | XXX | 16.9x | XXX | XXX | XXX |
| EV/EBITDA | -13.6x | XXX | -11.8x | XXX | XXX | XXX |
| EV/EBIT | -12.6x | XXX | -11.6x | XXX | XXX | XXX |
| EV/Gross Profit | 13.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -14.7x | XXX | -13.6x | XXX | XXX | XXX |
| EV/FCF | -27.4x | XXX | -16.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSpringWorks Therapeutics's last 12 month revenue growth is 79%
SpringWorks Therapeutics's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $1.2M for the same period.
SpringWorks Therapeutics's rule of 40 is -6187% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SpringWorks Therapeutics's rule of X is 103% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SpringWorks Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 79% | XXX | 79% | XXX | XXX | XXX |
| EBITDA Margin | -95% | XXX | -143% | XXX | XXX | XXX |
| EBITDA Growth | -57% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -6187% | XXX | -64% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 103% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 105% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 239% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SpringWorks Therapeutics acquired XXX companies to date.
Last acquisition by SpringWorks Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . SpringWorks Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SpringWorks Therapeutics founded? | SpringWorks Therapeutics was founded in 2017. |
| Where is SpringWorks Therapeutics headquartered? | SpringWorks Therapeutics is headquartered in United States of America. |
| How many employees does SpringWorks Therapeutics have? | As of today, SpringWorks Therapeutics has 368 employees. |
| Who is the CEO of SpringWorks Therapeutics? | SpringWorks Therapeutics's CEO is Mr. Saqib Islam, J.D.. |
| Is SpringWorks Therapeutics publicy listed? | Yes, SpringWorks Therapeutics is a public company listed on NAS. |
| What is the stock symbol of SpringWorks Therapeutics? | SpringWorks Therapeutics trades under SWTX ticker. |
| When did SpringWorks Therapeutics go public? | SpringWorks Therapeutics went public in 2019. |
| Who are competitors of SpringWorks Therapeutics? | Similar companies to SpringWorks Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of SpringWorks Therapeutics? | SpringWorks Therapeutics's current market cap is $3.5B |
| What is the current revenue of SpringWorks Therapeutics? | SpringWorks Therapeutics's last 12 months revenue is $251M. |
| What is the current revenue growth of SpringWorks Therapeutics? | SpringWorks Therapeutics revenue growth (NTM/LTM) is 79%. |
| What is the current EV/Revenue multiple of SpringWorks Therapeutics? | Current revenue multiple of SpringWorks Therapeutics is 12.9x. |
| Is SpringWorks Therapeutics profitable? | Yes, SpringWorks Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SpringWorks Therapeutics? | SpringWorks Therapeutics's last 12 months EBITDA is -$237M. |
| What is SpringWorks Therapeutics's EBITDA margin? | SpringWorks Therapeutics's last 12 months EBITDA margin is -95%. |
| What is the current EV/EBITDA multiple of SpringWorks Therapeutics? | Current EBITDA multiple of SpringWorks Therapeutics is -13.6x. |
| What is the current FCF of SpringWorks Therapeutics? | SpringWorks Therapeutics's last 12 months FCF is -$118M. |
| What is SpringWorks Therapeutics's FCF margin? | SpringWorks Therapeutics's last 12 months FCF margin is -47%. |
| What is the current EV/FCF multiple of SpringWorks Therapeutics? | Current FCF multiple of SpringWorks Therapeutics is -27.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
